SEC Info - Penederm Inc - 10-Q

SEC Info

Home

My Interests

Help

Please Sign In

Penederm Inc · 10-Q · For 3/31/98

Filed On 5/7/98 · SEC File 0-23112 · Accession Number 858876-98-6

  As Of               Filer                 Filing     On/For/As Docs:Pgs

 5/07/98  Penederm Inc                      10-Q        3/31/98    2:16

Quarterly Report · Form 10-Q
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                      15     53K 
 2: EX-27       Financial Data Schedule                                1      5K

10-Q · Quarterly Report
Document Table of Contents

Page	(sequential)	\|	(alphabetic)	Top
			Alternative Formats (RTF, XML, et al.) Financial Statements
1	1st Page
2	Item 1. Financial Statements

10-Q 1st Page of 15 TOC Top Previous Next Bottom Just 1st
 Sponsored Ads...







UNITED STATES               
SECURITIES AND EXCHANGE COMMISSION                
Washington, DC  20549               

Form 10-Q               

[ X ]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE                  
SECURITIES EXCHANGE ACT OF 1934                                                 

For the quarterly period ended      March 31, 1998                              

Commission File Number              0-22314                                     

PENEDERM INCORPORATED                     
(Exact name of registrant as specified in its charter)                    

DELAWARE                            77-0146116                    
(State of other jurisdiction of      I.R.S. Employer Identification Number      
incorporation or organization)                                                  

320 LAKESIDE DRIVE   FOSTER CITY,  CALIFORNIA           94404           
(Address of principal executive offices)             (Zip Code)         

(650) 358-0100                        
(Registrant's telephone number, including area code)                

Indicate by check whether the registrant (1) has filed all                      
reports required to be filed by section 13 or 15(d) of the                      
Securities Exchange Act of 1934 during the preceding 12 month (or               
for such shorter period that the registrant was required to file                
such reports), and (2) has been subject to such filing                          
requirements for the past 90 days.                                              

YES    X       NO                       

Indicate number of shares outstanding of each of the issuer's                   
classes of common stock, at the latest practicable date:                        

Class                         Outstanding as of: MARCH 31, 1998                 
-----                         ---------------------------------                 
Common Stock                         8,256,057                                  

10-Q 2nd Page of 15 TOC 1st Previous Next Bottom Just 2nd

PENEDERM INCORPORATED               
TABLE OF CONTENTS               
FORM 10-Q               

                                                    Page
                                                    Number
                                                    ------
PART I.   FINANCIAL INFORMATION                                                 

Item 1.   Financial Statements                                                  

Condensed Consolidated Balance Sheets-                      
 March 31, 1998 and December 31, 1997                  3

Condensed Consolidated Statements of Operations-            
 Three months ended March 31, 1998 and 1997            4

Condensed Consolidated Statements of Cash Flows-            
 Three months ended March 31, 1998 and 1997            5

Notes to Condensed Consolidated Financial Statements     6  

Item 2.   Management's Discussion and Analysis                                  
of Financial Condition and Results of Operations         7  

PART II.  OTHER INFORMATION                                                     

Item 2.   Sale of Unregistered Securities                         13            

Item 6.   Exhibits and Reports on Form 8-K                        13            

Signature Page                                                    14            

10-Q 3rd Page of 15 TOC 1st Previous Next Bottom Just 3rd

PENEDERM INCORPORATED         
CONDENSED CONSOLIDATED BALANCE SHEETS         
March 31, 1998 and December 31, 1997        
(in thousands)        

                                              March 31,         December 31,
                                              1998                1997
                                            -----------        -----------
                                           (unaudited)            (Note)
ASSETS                                                                          
Current assets:                                                                 
Cash and cash equivalents                     $   1,608          $   1,519  
Short-term marketable securities                  1,000              3,102  
Accounts receivable                               2,760              1,013  
Inventory                                         1,962              1,501  
Prepaid expenses and other current assets           654                466  
                                             ----------         ----------
Total current assets                                7,984              7,601    

Marketable securities                                 -              1,000  
Property and equipment, at cost, less                                       
accumulated depreciation and amortization         304                267
Intangible and other assets                       1,746              1,363  
                                             ----------         ----------
Total assets                                    $  10,034          $  10,231    
                                             ==========         ==========

LIABILITIES                                                                     
Current liabilities:                                                            
Accounts payable                              $   1,321          $   1,264  
Accrued liabilities                               3,982              3,763  
                                             ----------         ----------
Total current liabilities                           5,303              5,027    

Long-term obligations                                   8                 10    
                                             ----------         ----------
Total liabilities                                   5,311              5,037    

STOCKHOLDERS' EQUITY                                                            
Common stock, $.01 par value                           83                 82    
Additional paid-in capital                         57,160             56,222    
Accumulated deficit                               (52,520)           (51,110)   
                                              ----------        ----------
Total stockholders' equity                          4,723              5,194    
                                              ----------        ----------
Total liabilities and stockholders' equity       $ 10,034          $  10,231    
                                              ==========        ==========

See accompanying notes.                                                         
Note:    The condensed consolidated  balance sheet at December 31, 1997 has been
derived from audited financial statements as of that date.                      

10-Q 4th Page of 15 TOC 1st Previous Next Bottom Just 4th

PENEDERM INCORPORATED             
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS             
(in thousands except per share data)            
(unaudited)             

                                Three Months Ended
                                 March 31,
                                ------------------
                                1998          1997
                                ----          ----

Revenues:                                                                       
Product sales                               $   2,730    $   2,601              
Licensing revenues                              1,271          300              
                               ----------   ----------
Total revenues                                  4,001        2,901              
                               ----------   ----------
Costs and expenses:                                                             
Cost of product sales                             726          763              
Research and development                        2,392        1,223              
Sales and marketing                             1,829        2,163              
General and administrative                        508          328              
                               ----------   ----------
Total costs and expenses                        5,455        4,477              
                               ----------   ----------
Loss from operations                           (1,454)      (1,576)             

Interest income, net                               44           59              
                               ----------   ----------
Net loss                                     $ (1,410)    $ (1,517)             
                               ==========   ==========
Basic and diluted net loss per share         $  (0.17)    $  (0.20)             
                               ==========   ==========
Number of shares used in computing basic                                        
and diluted net loss  per share               8,191        7,583            
                               ==========   ==========

See accompanying notes.                                                         

10-Q 5th Page of 15 TOC 1st Previous Next Bottom Just 5th

PENEDERM INCORPORATED                 
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS                 
(in thousands)                  
(unaudited)                 

                                                      Three Months Ended
                                                     March 31,
                                                      ------------------
Increase (decrease) in cash and cash equivalents          1998          1997    
                                                      ----          ----
Cash flows from operating activities:                                           
Net loss                                               $ (1,410)     $ (1,517)  
Adjustments to reconcile net loss to net cash used                              
in operating activities:                                                    
Depreciation and amortization                                94            81   
Increase in accounts receivable                          (1,747)       (2,785)  
Increase in inventory                                      (461)         (166)  
Increase in prepaid expenses and other                                          
   current assets                                        (188)         (587)
Increase in accounts payable and accrued                                        
  liabilities                                            278           763
Increase in other assets                                    (32)           (2)  
                                                      --------      --------
Net cash used in operating activities                    (3,466)       (4,213)  
                                                      --------      --------

Cash flows from investing activities:                                           
Purchases of available-for-sale securities                    -        (5,013)  
Maturities of available-for-sale securities               2,102           253   
Sales of available-for-sale securities                    1,000           249   
Acquisition of intangible assets                           (400)            -   
Acquisition of fixed assets                                 (82)          (43)  
                                                      --------      --------
Net cash provided by (used in) investing activities       2,620        (4,554)  
                                                      --------      --------

Cash flows from financing activities:                                           
Issuance of common stock in private placement                 -         8,975   
Issuance of common stock under equity line of credit        890             -   
Proceeds from issuance of common stock                       49            90   
Repayment of long-term obligations                           (4)           (3)  
                                                      --------      --------
Net cash provided by financing activities                   935         9,062   
                                                      --------      --------

Net increase in cash and cash equivalents                    89           295   
Cash and cash equivalents at beginning of period          1,519         3,062   
                                                      --------      --------
Cash and cash equivalents at end of period              $ 1,608       $ 3,357   
                                                      ========      ========

See accompanying notes.                                                         

10-Q 6th Page of 15 TOC 1st Previous Next Bottom Just 6th

PENEDERM INCORPORATED               
NOTES TO  CONDENSED CONSOLIDATED FINANCIAL STATEMENTS               
(unaudited)               

1.  Interim Unaudited Financial Information                           

The    accompanying    interim   unaudited    condensed               
consolidated   financial   statements    of    Penederm               
Incorporated (the Company) for the three month  periods               
ended  March 31, 1998 and 1997,  have been prepared  in               
accordance    with   generally   accepted    accounting               
principles for interim financial statements and include               
all  adjustments  (consisting of normal  and  recurring               
adjustments) that the Company considers necessary for a               
fair  presentation of the operating  results  and  cash               
flows for these periods. The results of operations  for               
the  interim periods are not necessarily indicative  of               
the  results to be expected for an entire year.   These               
financial statements should be read in conjunction with               
the audited financial statements and notes included  as               
part  of  the  Company's Form 10-K for the  year  ended               
December 31, 1997.                                                    

2.  Inventory                                                         

Inventories are stated at the lower of cost  (first-in,               
first-out) or market and consisted of the following:                  

         March 31,      December 31,
(In thousands)              1998             1997                     
       ----             ----
Raw materials             $   691          $   572                    
Finished goods              1,271              929                    
      -------          -------
      $ 1,962          $ 1,501
      =======          =======

3.  Net Loss Per Share                                                

Net  loss  per  share  is computed using  the  weighted               
average number of common shares outstanding during  the               
period.   Common  stock equivalents relating  to  stock               
options  are  excluded  from the computation  as  their               
effect is anti-dilutive.                                              

4.  Comprehensive Income                                              

As of January 1, 1998, the company adopted Statement of               
Financial Accounting Standard (SFAS) No. 130, Reporting               
Comprehensive Income.  SFAS 130 establishes  new  rules               
for  the reporting and display of comprehensive  income               
and  its  components;  however, the  adoption  of  this               
statement  had no impact on the Company's net  loss  or               
stockholders' equity.                                                 

10-Q 7th Page of 15 TOC 1st Previous Next Bottom Just 7th

Part I Item  2.  Management's  Discussion  and  Analysis  of                    
Financial Condition and Results of Operations 

Forward Looking Statements                                  

The statements in "Management's Discussion and Analysis     
of  Financial Condition and Results of Operations" that     
relate   to   future  plans,  events  or   performance,     
including  statements relating to  future  revenue  and     
expense  levels,  are forward-looking statements  which     
involve  risks  and  uncertainties including,  but  not     
limited  to, product development and market  acceptance     
risks,  product  manufacturing risks, risks  associated     
with the establishment and management of a sales force,     
the  development of competitive therapies, the  pricing     
of  competitive therapies, the results of  current  and     
future licensing and other collaborative relationships,     
the   results   of   financing  efforts,   developments     
regarding  intellectual property rights and litigation,     
risks of product nonapproval or delays or post-approval     
reviews  by  the FDA or foreign regulatory authorities,     
and other risks identified in the Company's most recent     
Form  10-K and other Securities and Exchange Commission     
filings.   Actual  results, events or  performance  may     
differ materially. The Company undertakes no obligation     
to  update these forward-looking statements to  reflect     
events  or  circumstances after the date hereof  or  to     
reflect the occurrence of unanticipated events.             

Recent  Events                                              

Penederm announced in January 1998 that it had  entered     
into   an  agreement  with  Alpharma  Inc.,  a  leading     
multinational   pharmaceutical   company,   to   market     
Alpharma's  recently approved permethrin cream  5%  for     
the  treatment of sarcoptes scabiei (scabies infection)     
under its trade name Acticin.  In February, the Company     
announced that it had received approval from the United     
States Food and Drug Administration to market its Avita     
gel  product in the United States for the treatment  of     
acne. Penederm recently commenced the commercial launch     
of  Avita  gel  and Acticin, increasing the  number  of     
dermatologic  pharmaceutical products  offered  by  the     
Company to four.                                            

On  March  31  1998,  the Company amended  its  current     
agreement with Kaken Pharmaceutical Co. Ltd. to provide     
the  Company with an option to develop and market  oral     
forms  of  butenafine (the active drug  in  Mentax)  in     
North  and South America.  If the option for  the  oral     
form  of butenafine is exercised, and assuming an  oral     
drug  product  could  be  successfully  developed,  the     
development process would be expected by management  to     
take  several  years  before  such  product  could   be     
commercialized.                                             

10-Q 8th Page of 15 TOC 1st Previous Next Bottom Just 8th

During  the  first  quarter of 1998,  the  Company  met     
certain  development  milestones  under  one   of   its     
agreements with SmithKline Beecham plc.  The  agreement     
involves the co-development by the companies of  a  new     
formulation of an undisclosed currently marketed  over-     
the-counter  (OTC) topical product.   The  Company  was     
paid  a  related  development  milestone  payment   and     
intends  to negotiate a final license agreement related     
to the product during the second quarter of 1998.           

In  March  1998, the Company entered into an  agreement     
for  generic  tretinoin 0.025% cream to be manufactured     
by its contract manufacturer for an undisclosed generic     
pharmaceutical  company.   The  Company  believes  that     
Retin-A  (Ortho) has 97% of the 0.025% cream  tretinoin     
market segment.  The Company will receive royalties and     
certain other minimum payments under the agreement.         

Penederm also met certain development milestones for  a     
topical  nail antifungal product being co-developed  by     
the  Company  and  Schering-Plough HealthCare  Products     
Inc.  and  was paid a related milestone payment  during     
the  quarter.  The Company also reacquired  promotional     
rights   related   to   the   podiatry   promotion   of     
prescription Mentax cream effective April 15, 1998.         

Overview                                                              

Penederm  is  a pharmaceutical company that specializes     
in   developing  and  marketing  dermatology  products.     
Penederm  now  offers  four prescription  topical  drug     
treatments to dermatologists:                               

- Mentax,  a  prescription topical cream treatment      
for  three  skin fungal conditions: tinea  pedis    
(athlete's foot), tinea corporis (ringworm)  and    
tinea cruris (groin fungus)                         

- Avita cream   and   gel,   prescription   topical     
treatments for acne, and                            

- Acticin,  a prescription topical cream treatment      
for scabies infection.                              

10-Q 9th Page of 15 TOC 1st Previous Next Bottom Just 9th

Penederm has several other pharmaceutical products  for     
fungal  inflammatory conditions, psoriasis, nail fungus     
and  Mentax  skin  treatment line extensions  in  human     
clinical  trials. The Company also sells  its  patented     
TopiCare   Delivery Compounds  for use in cosmetics and     
personal  care products, and markets its own  over-the-     
counter   (OTC)  skin  care  products.   Penederm   has     
established  collaborative  relationships  with   other     
pharmaceutical companies as follows:                        

COMPANY                  PRODUCT AREA                 TERRITORY 
-------                  ------------                 --------- 
In-License and Co-                                                              
Development Agreements:                                                         
-----------------------                                                         
Kaken Pharmaceutical     Penederm in-licensed          United States, Canada,   
Company Ltd. (Kaken)     butenafine, the active        Mexico and Latin         
                ingredient incorporated in    America for skin
                 Mentax                        antifungal; U.S.,
                                                     Canada, Europe, Mexico,
                                            Latin America,
                                               Australia and New
                                              Zealand for nail
                                        antifungal

SmithKline Beecham plc   Undisclosed OTC product       SmithKline option to     
(SmithKline)                                           market worldwide         

Alpharma, Inc.           Acticin for scabies           United States            
(Alpharma)                                                                      

Out-License Agreements:                                                         
-----------------------                                                         
Schering-Plough          Prescription and OTC skin     United States and        
HealthCare               antifungal and nail           Canada                   
Products, Inc.           antifungal                                             
(Schering-Plough)                                                               

UCB Group of Belgium     Prescription antifungal       Europe, Africa and       
(UCB)                    products                      Middle East              

Warner Wellcome Consumer OTC dry skin                  Canada                   
Health Products (Warner)                                                        

SmithKline               OTC consumer products         Europe and Eastern       
                                    Europe

Pierre Fabre Inc.        DuraScreen sunscreen          United States            
(Pierre Fabre)                                                                  

Allergan, Inc.           Butenafine topical            Central and South        
(Allergan)               antifungal and retinoic       America                  
acid cream and gel            

Mylan Laboratories, Inc. Co-promote Mentax cream to    United States            
(Mylan)                  primary care physicians                                

10-Q 10th Page of 15 TOC 1st Previous Next Bottom Just 10th

The  Company  has  been  unprofitable  since inception.     
For  the period from inception through March 31,  1998,     
the   Company  incurred  a  cumulative  net   loss   of     
$52,520,000.   Penederm's sources  of  working  capital     
have been equity financings, product sales to corporate     
partners,  sales  of Mentax, Avita and over-the-counter     
products,  product  license  fees,  sales  of  TopiCare     
Delivery Compounds and interest earned on investments.      

Results of Operations                                       

Three Months Ended March 31, 1998 and 1997                  

Total  revenues  for  the three months ended  March 31,     
1998  of  $4,001,000 increased 38%  from  $2,901,000 in     
the  same  period of 1997.  The first quarter  of  1998     
reflects  product  revenues of  $2,730,000  from  Avita     
cream  and  Mentax  sales  and  initial  product  stock     
shipments  of  the Company's recently launched  Acticin     
and Avita gel products.  Product revenues of $2,601,000     
in  the  first  quarter of 1997 consisted primarily  of     
initial  product  stocking shipments of  the  Company's     
first   pharmaceutical  product,   Mentax.    Licensing     
revenues  increased to $1,271,000 in the first  quarter     
of  1998,  compared to $300,000 in the same quarter  of     
the prior year, as a result of increased attainment  of     
performance   milestones   under   various    corporate     
partnering  arrangements in 1998 versus the  comparable     
prior year period.                                          

The Company's  cost of sales  decreased to  $726,000 in     
the  three  months  ended  March 31, 1998 from $763,000     
in the same period of 1997 primarily due to a change in     
revenue mix favoring higher margin products.                

10-Q 11th Page of 15 TOC 1st Previous Next Bottom Just 11th

The   Company's   research  and  development   expenses     
increased  96% to $2,392,000 in the three months  ended     
March  31,  1998 from $1,223,000 in the same period  of     
1997  due  to  the  timing and size of  human  clinical     
trials.   The  Company commenced two  Phase  III  human     
clinical  studies of its 501 cream combination  product     
during  the  third quarter of 1997.  These studies  are     
being  conducted at over 32 clinical sites and  involve     
over  1,600  patients.   Sales and  marketing  expenses     
decreased to $1,829,000 in the three months ended March     
31,  1998 from $2,163,000 for the same period of  1997.     
The  prior  year period includes costs related  to  the     
initial  launch  of the Company's first  drug  product.     
These  costs did not recur in 1998, but were  partially     
replaced  by  increased costs related to  internalizing     
the  Company's sales force.  General and administrative     
expenses increased 55% to $508,000 in the three  months     
ended  March 31, 1998 from $328,000 in the same  period     
of  1997.  General and administrative expenses  in  the     
first quarter of 1997 reflect a recovery of legal  fees     
related to prior patent litigation.                         

Net  interest  income was $44,000 in the  three  months     
ended March 31, 1998 and $59,000 in the same period  of     
1997.                                                       

The Company expects that annual revenues, and costs and     
expenses  will continue to increase in the future,  due     
principally   to  further  commercialization   of   its     
pharmaceutical products.  Sales and marketing  expenses     
are  expected to increase significantly from the  prior     
year reflecting the increased costs associated with its     
sales  force.  The Company also expects some  expansion     
of  research and development programs, increased patent     
and regulatory costs, expansion of regulatory, clinical     
and   quality  assurance  capabilities,  and  increased     
administrative support costs.                               

In  addition,  sales of a product upon  initial  market     
introduction generally include a significant amount  of     
initial   orders  for  inventory  by  wholesalers   and     
distributors  and  are  not necessarily  indicative  of     
actual   demand  for  that  product  by  patients   and     
physicians.    There   can   be   no   assurance   that     
distributors and wholesalers will be able  to  forecast     
demand   for   product  accurately.   Fluctuations   in     
operating  results will occur to the extent  that  sell     
through  of  products  does not meet  distributors'  or     
wholesalers'  expectations.  The Company  also  expects     
that  future  operating  results  may  be  subject   to     
quarterly  variations that may impact  cash  flow  from     
operations.   Operating results for  the  three  months     
ended March 31, 1998 are not necessarily indicative  of     
future operating results.                                   

10-Q 12th Page of 15 TOC 1st Previous Next Bottom Just 12th

Liquidity and Capital Resources                             

The  Company's  principal  sources  of  capital to date     
have   been  the  proceeds  from  public  and   private     
offerings of its equity securities, including  a  March     
1997  private placement for which the net proceeds were     
approximately $9,000,000.  In January 1998, the Company     
entered into an agreement with an investment group  for     
an  equity  line of credit which allows the Company  to     
access  up  to $10 million through sales of its  common     
stock over a period ending in April 2000.  At March 31,     
1998,  the  Company  had  cash,  cash  equivalents  and     
investments  totaling   $2,608,000,  and  approximately     
$9  million  was  available  under  the  equity line of     
credit.                                                     

Cash expenditures related to operating activities,  the     
acquisition of fixed assets and repayment of  long-term     
obligations  totaled  $3,552,000 in  the  three  months     
ended March 31, 1998 and $4,259,000 for the same period     
in   1997.   Operating  activities  were  comprised  of     
research  and  development,  clinical  trials,  product     
sales, promotion and general administration activities.     
The  Company  also made milestone payments of  $400,000     
related  to the in-licensing of drug compounds  in  the     
three   months  ended  March  31,  1998.   No   similar     
milestone payments were made in the first three  months     
of  1997.   The  Company expects that amounts  expended     
historically  are not indicative of future expenditures     
by   the  Company,  which  the  Company  believes  will     
increase.   The  Company expects to continue  to  incur     
substantial   expenditures  related  to   the   further     
research   and   development   of   its   technologies,     
development of its products, acquisition of  additional     
products  and  rights to drug compounds and  sales  and     
marketing.                                                  

The   Company  believes  that  its  capital  resources,     
including  anticipated revenues (consisting of  product     
sales,  license  fees  and  royalties),  proceeds  from     
sales   of   common   stock    under    the      equity     
line   of   credit   and    interest  income  earned on     
its   invested   cash   balances,   will   satisfy  the     
Company's   working  capital  and  identified   capital     
expenditure  requirements at least  through  March  31,     
1999.  The  Company's future capital requirements  will     
depend   on  many  factors,  including  the  commercial     
success  of  the  Company's products, progress  of  the     
Company's  collaborative and independent  research  and     
development    programs,   payments   received    under     
collaborative agreements with other companies, if  any,     
the  results  and  costs  of preclinical  and  clinical     
testing   for   the  Company's  products,   the   costs     
associated with and the timing of regulatory approvals,     
technological  advances,  the  status  of   competitive     
products,  and  the  commercial success  of  Penederm's     
strategic  relationships.  There can  be  no  assurance     
that  additional funds will be available to the Company     
on favorable terms, if at all, to permit the Company to     
continue with its current plan for operations.              

10-Q 13th Page of 15 TOC 1st Previous Next Bottom Just 13th

Part II Item 2.  Sales of Unregistered Securities                               

The Company issued an aggregate of 96,983 shares of its     
Common   Stock   (the  "Shares")   for   an   aggregate     
consideration   of   $988,500   in   an    unregistered     
transaction in the fiscal quarter ended March 31, 1998.     
The  Shares  were issued pursuant to the  Common  Stock     
Investment  Agreement  dated as  of  January  21,  1998     
between  the  Company and Promethean Investment  Group,     
L.L.C. (the "Investor").  Based on representations made     
by  the  Investor in the Agreement, the Company  issued     
the  Shares  pursuant  to  the  exemption  provided  by     
Section 4(2) of the Securities Act of 1933, as amended.     

Part II Item 6.  Exhibits and Reports on Form 8-K                               

(a)       Exhibits                                          

27             Financial Data Schedule                                

(b)     Reports on Form 8-K                             

None.                                   

10-Q 14th Page of 15 TOC 1st Previous Next Bottom Just 14th

SIGNATURES                

Pursuant  to the requirements of the Securities and Exchange  Act               
of  1934, the registrant has duly caused this report to be signed               
on its behalf by the undersigned, thereunto duly authorized.                    

           PENEDERM INCORPORATED

May 7, 1998                /s/   Lloyd H. Malchow                     
-----------                --------------------------------           
Date                       Lloyd H. Malchow, President                
           and Chief Executive Officer

May 7, 1998                /s/   Michael A. Bates                     
-----------                --------------------------------           
Date                       Michael A. Bates, Vice President           
              Finance and Administration and
       Chief Financial Officer

10-Q Last Page of 15 TOC 1st Previous Next Bottom Just 15th

INDEX TO EXHIBITS               

Exhibit                                                         
No.      Description                                      
-------     -----------                                         

27        Financial Data Schedule

10-Q	1st Page of 15	TOC	Top	Previous	Next	Bottom	Just 1st

10-Q	2nd Page of 15	TOC	1st	Previous	Next	Bottom	Just 2nd

10-Q	3rd Page of 15	TOC	1st	Previous	Next	Bottom	Just 3rd

10-Q	4th Page of 15	TOC	1st	Previous	Next	Bottom	Just 4th

10-Q	5th Page of 15	TOC	1st	Previous	Next	Bottom	Just 5th

10-Q	6th Page of 15	TOC	1st	Previous	Next	Bottom	Just 6th

10-Q	7th Page of 15	TOC	1st	Previous	Next	Bottom	Just 7th

10-Q	8th Page of 15	TOC	1st	Previous	Next	Bottom	Just 8th

10-Q	9th Page of 15	TOC	1st	Previous	Next	Bottom	Just 9th

10-Q	10th Page of 15	TOC	1st	Previous	Next	Bottom	Just 10th

10-Q	11th Page of 15	TOC	1st	Previous	Next	Bottom	Just 11th

10-Q	12th Page of 15	TOC	1st	Previous	Next	Bottom	Just 12th

10-Q	13th Page of 15	TOC	1st	Previous	Next	Bottom	Just 13th

10-Q	14th Page of 15	TOC	1st	Previous	Next	Bottom	Just 14th

10-Q	Last Page of 15	TOC	1st	Previous	Next	Bottom	Just 15th

Dates Referenced Herein and Documents Incorporated By Reference

		Referenced-On Page
This 10-Q Filing	Date	First	Last	Other Filings

	3/31/97	2	10	10-Q
	12/31/97	3	6	10-K
	1/1/98	6
	1/21/98	13
For The Period Ended	3/31/98	1	13
	4/15/98	8
Filed On / Filed As Of	5/7/98	14
	3/31/99	12

Top				List All Filings

Filing Submission - Alternative Formats (Word / Rich Text, HTML, Plain Text, SGML, XML, et al.)

Penederm Inc · 10-Q · For 3/31/98

Filed On 5/7/98 · SEC File 0-23112 · Accession Number 858876-98-6

Quarterly Report · Form 10-QFiling Table of Contents

10-Q · Quarterly ReportDocument Table of Contents

Dates Referenced Herein and Documents Incorporated By Reference

Quarterly Report · Form 10-Q
Filing Table of Contents

10-Q · Quarterly Report
Document Table of Contents